Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders.
Wedemeyer H, Di Marco V, Garcia-Retortillo M, Teti E, Fraser C, Morano Amado LE, Rodriguez-Tajes S, Acosta-López S, O'Loan J, Milella M, Buti M, Guerra-Veloz MF, Ramji A, Fenech M, Martins A, Borgia SM, Vanstraelen K, Mertens M, Hernández C, Ntalla I, Ramroth H, Milligan S. Wedemeyer H, et al. Among authors: garcia retortillo m. Viruses. 2022 Nov 11;14(11):2493. doi: 10.3390/v14112493. Viruses. 2022. PMID: 36423102 Free PMC article.
Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.
Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, Gutiérrez ML, Suárez E, Gómez Rubio M, López J, Castillo P, Rodríguez M, Zozaya JM, Simón MA, Morano LE, Calleja JL, Yébenes M, Esteban R. Buti M, et al. PLoS One. 2017 Sep 12;12(9):e0184550. doi: 10.1371/journal.pone.0184550. eCollection 2017. PLoS One. 2017. PMID: 28898281 Free PMC article. Clinical Trial.
A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA, Gonzalez-Colominas E, García-Retortillo M, Cañete N, Cirera I, Coll S, Giménez MD, Márquez C, Martin-Escudero V, Castellví P, Navinés R, Castaño JR, Galeras JA, Salas E, Bory F, Martín-Santos R, Solà R. Carrión JA, et al. J Hepatol. 2013 Nov;59(5):926-33. doi: 10.1016/j.jhep.2013.06.019. Epub 2013 Jun 26. J Hepatol. 2013. PMID: 23811030 Clinical Trial.
53 results